Genetic biomarkers of methotrexate response and safety in Crohn's disease: Data from the Spanish ENEIDA registry.

doi:10.1111/bcp.16017

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Genetic biomarkers of methotrexate response and safety in Crohn's disease: Data from the Spanish ENEIDA registry.

British journal of clinical pharmacology - 1 May 2024

Salazar Juliana, Garcia-Planella Esther, Fernández-Clotet Agnès, Esteve Maria, Gisbert Javier P, Busquets David, Lucendo Alfredo, Márquez Lucía, Guardiola Jordi, Martín-Arranz María Dolores, Iglesias Eva, Monfort David, Villoria Albert, Cañete Fiorella, Bell Olga, Ricart Elena, Zabana Yamile, Chaparro María, Domènech Eugeni, Gordillo Jordi

Abstract excerpt

AIMS: Methotrexate (MTX) is used to induce and maintain remission in patients with steroid-dependent Crohn's disease (CD). Despite its proven efficacy, its use is limited due to associated adverse events. Polymorphisms involving folate pathway genes might influence MTX efficacy and toxicity. We aimed to assess the impact of certain polymorphisms on the therapeutic outcomes of MTX in CD. METHODS: Patients with CD...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Crohn Disease

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunosuppressive Agents

Share to Methotrexate

Share to Methylenetetrahydrofolate Reductase (NADPH2)

Share to Registries

Share to Remission Induction

Share to Spain

Share to Treatment Outcome

Source

Open in PubMed

Identifiers

PMID: 38369687
DOI: 10.1111/bcp.16017

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic biomarkers of methotrexate response and safety in Crohn's disease: Data from the Spanish ENEIDA registry.PMID 38369687Read ↗

Prediction of methotrexate clinical response in Portuguese rheumatoid arthritis patients: implication of MTHFR rs1801133 and ATIC rs4673993 polymorphisms.Semantic proximity Read ↗

Pharmacogenetics of Inflammatory Bowel DiseaseSemantic proximity Read ↗

Effects of various genetic polymorphisms on thiopurine treatment-associated outcomes for Korean patients with Crohn's disease.Semantic proximity Read ↗

The pharmacogenetics of methotrexate in inflammatory bowel disease.Semantic proximity Read ↗

Polymorphisms and Pharmacogenomics for the Clinical Efficacy of Methotrexate in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-analysis.Semantic proximity Read ↗

The impact of folate pathway variants on the outcome of methotrexate therapy in rheumatoid arthritis patients.Semantic proximity Read ↗

Pharmacogenetics of inflammatory bowel disease: a focus on Crohn's disease.Semantic proximity Read ↗

Influence of FPGS rs1544105 and GGH rs3758149 Gene Polymorphisms on Methotrexate Pharmacogenetics.Semantic proximity Read ↗

Effect of Genetic Polymorphisms in the Folate Pathway on Methotrexate Therapy in Rheumatic DiseasesSemantic proximity Read ↗

Polymorphisms in genes involved in the mechanism of action of methotrexate: are they associated with outcome in rheumatoid arthritis patients?Semantic proximity Read ↗

Using pharmacogenetics to predict methotrexate response in rheumatoid arthritis patients.Semantic proximity Read ↗

Treatment of Chronic Inflammatory Diseases – The Potential of PharmacogeneticsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.